Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Odile Launay

Showing results (261-270 of 305) with videos related to

Pageof 31
Sort By:
Advances in Therapy|December 16, 2024
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised IndividualsChristoph D Spinner, Samira Bell, Hermann Einsele, et al.
Human Vaccines & Immunotherapeutics|October 4, 2016
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysisGuillermo M Ruiz-Palacios, Geert Leroux-Roels, Jiri Beran, et al.
Vaccine|November 11, 2025
Rotasiil vaccine effectiveness against rotavirus-associated hospitalizations in the Democratic Republic of the Congo: comparison of multivariate logistic regression and inverse probability treatment weighting methods in a test-negative designChristophe Luhata Lungayo, Eleanor Burnett, Audry Mulumba, et al.
Journal of Gynecology Obstetrics and Human Reproduction|March 16, 2024
Maternal and neonatal outcomes of French prospective multicenter cohort study COVIPREG during the first two COVID-19 wavesAlexandre J Vivanti, Camille Couffignal, Jeanne Sibiude, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 19, 2017
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 seasonMarc Rondy, Alin Gherasim, Itziar Casado, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2014
Prevention of infections during primary immunodeficiencyClaire Aguilar, Marion Malphettes, Jean Donadieu, et al.
Journal of Crohn'S & Colitis|September 10, 2015
Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective StudyOdile Launay, Vered Abitbol, Anne Krivine, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 3, 2022
Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up: analyses stratified by gender from a large prospective cohortJade Ghosn, Delphine Bachelet, Marine Livrozet, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 17, 2022
One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohortPaul Loubet, Linda Wittkop, Laetitia Ninove, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Pageof 31

Showing results (261-270 of 305) with videos related to

Sort By:
Pageof 31
Advances in Therapy|December 16, 2024
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised IndividualsChristoph D Spinner, Samira Bell, Hermann Einsele, et al.
Human Vaccines & Immunotherapeutics|October 4, 2016
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysisGuillermo M Ruiz-Palacios, Geert Leroux-Roels, Jiri Beran, et al.
Vaccine|November 11, 2025
Rotasiil vaccine effectiveness against rotavirus-associated hospitalizations in the Democratic Republic of the Congo: comparison of multivariate logistic regression and inverse probability treatment weighting methods in a test-negative designChristophe Luhata Lungayo, Eleanor Burnett, Audry Mulumba, et al.
Journal of Gynecology Obstetrics and Human Reproduction|March 16, 2024
Maternal and neonatal outcomes of French prospective multicenter cohort study COVIPREG during the first two COVID-19 wavesAlexandre J Vivanti, Camille Couffignal, Jeanne Sibiude, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 19, 2017
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 seasonMarc Rondy, Alin Gherasim, Itziar Casado, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2014
Prevention of infections during primary immunodeficiencyClaire Aguilar, Marion Malphettes, Jean Donadieu, et al.
Journal of Crohn'S & Colitis|September 10, 2015
Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective StudyOdile Launay, Vered Abitbol, Anne Krivine, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 3, 2022
Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up: analyses stratified by gender from a large prospective cohortJade Ghosn, Delphine Bachelet, Marine Livrozet, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 17, 2022
One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohortPaul Loubet, Linda Wittkop, Laetitia Ninove, et al.
Plos Pathogens|June 27, 2020
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II TrialYves Lévy, Christine Lacabaratz, Kim Ellefsen-Lavoie, et al.
Pageof 31